Is KVUE a buy according to AI stock analysis?

KVUE AI stock analysis does not label the stock a universal buy because the setup is merger-linked and investor-specific. The page rates Kenvue as a defensive brand portfolio with moderate investment certainty, positive but neutral technical momentum, and important risks from the Kimberly-Clark transaction, KMB share exposure, legal claims, and low organic growth.

What is the KVUE AI stock forecast?

The KVUE AI stock forecast uses scenarios rather than a fixed target: bearish $12 to $15, base $18.5 to $21, and bullish $21 to $24. The near-term path is anchored by the cash-and-stock consideration of about $19.49 per share, which floats with the Kimberly-Clark share price.

What technical levels matter for KVUE?

The key KVUE technical levels are support near $18.95 to $19.10, deeper support near the 50-day moving average at $18.53, long-term support near the 200-day moving average at $17.52, and resistance near the $19.83 to $20.05 zone up to the analyst target and the recent high.

Can AI predict KVUE stock price?

No, AI cannot reliably predict stock prices. For KVUE, AI can organize filings, merger terms, market data, technical levels, and scenario math, but the actual price can change with Kimberly-Clark shares, regulatory approvals, Q2 results on August 6, litigation news, earnings, rates, and market sentiment.

How should I use this KVUE AI trading strategy?

Use this KVUE AI trading strategy as a research checklist, not as personal financial advice. Confirm live prices, track merger updates and the August 6 Q2 report, compare the implied cash-and-stock consideration with the market price, size risk before entry, and define invalidation levels before acting.

What does the Kimberly-Clark deal mean for KVUE stock?

The pending Kimberly-Clark acquisition offers KVUE shareholders $3.50 cash plus 0.14625 Kimberly-Clark shares per share, worth about $19.49 at the July 31, 2026 KMB close. That deal value acts as a reference point for the stock until the transaction completes or breaks.

Kenvue Inc. research snapshot

KVUE AI Stock Analysis

KVUE AI stock analysis reads Kenvue as a defensive consumer health company with trusted brands such as Tylenol, Listerine, Band-Aid, Neutrogena, Zyrtec, Aveeno, and Johnson's, but the stock remains tied to Kimberly-Clark pending cash-and-stock acquisition. At the August 2, 2026 data cutoff, KVUE closed near $19.24 on July 31, 2026, with a market capitalization near $36.94 billion, down 11.25% over the past 52 weeks. The Q1 2026 report, released May 7, beat estimates with net sales up 4.5% to $3.909 billion and adjusted EPS of $0.32 versus consensus near $0.26, while the board raised the quarterly dividend 1.2% to $0.21 on July 29. The pending Kimberly-Clark transaction still offers $3.50 cash plus 0.14625 Kimberly-Clark shares per KVUE share, which was worth about $19.49 at the July 31, 2026 KMB close of $109.31, slightly above the KVUE price. Risks include Tylenol autism and ADHD lawsuits revived by a federal appeals court on July 13, decongestant advertising claims, weak organic growth, KMB share price exposure, and transaction timing. The analysis supports a scenario framework, not a certain price prediction, and is for information only.

Current price

$19.24

Market cap

$36.94 billion

AI score

68 / 100

Rating

Defensive brands, merger-linked valuation

Trend status

Above the 50-day and 200-day moving averages, trading below the analyst target

Data cutoff (updated monthly)

August 4, 2026

Informational use only. This page is not investment advice.

Research quality check

information Richness: A-level information richness. Kenvue has public SEC filings, quarterly releases, segment data, liquid NYSE trading, broad analyst coverage of 14 firms, and pending merger filings, so most key figures can be checked against multiple sources.
bias Check: The main AI bias risk is treating KVUE as a normal stand-alone consumer staples stock while under-weighting the Kimberly-Clark transaction terms, KMB share consideration exposure, the August 6 Q2 earnings date, Tylenol litigation headlines, and low organic growth. The reverse check asks whether the deal spread, legal overhang, and weak organic volume explain why the stock stays below the $19.49 implied deal value.
ai Confidence: High for reported FY2025 and Q1 2026 financials, share count, market cap math, valuation ratios, and technical indicators that cross-validated across StockAnalysis.com, Barchart, and company releases. Medium for forward valuation because KVUE now trades partly as a merger-spread and KMB-linked security and Q2 2026 results have not yet been released.
investment Certainty: Medium. The brands are durable and cash flow is real, but investment certainty is capped by transaction completion risk, KMB share price exposure, litigation, and modest stand-alone growth.

Quick verdict table

Dimension	Conclusion	Confidence
Business quality	Kenvue sells everyday consumer health products across Self Care, Skin Health and Beauty, and Essential Health, with TTM revenue near $15.29 billion and repeated usage behind trusted brands.	High
Moat	The moat comes from brand trust, pharmacist and healthcare professional recommendations, shelf space, distribution scale, regulatory know-how, and product familiarity.	Medium-high
Management	Management is operating through a pending Kimberly-Clark acquisition, so execution must be judged through deal progress, integration planning, productivity savings, brand stabilization, and the August 6 Q2 2026 report.	Medium
Financial trend	FY2025 net sales fell 2.1% to $15.124 billion, while Q1 2026 net sales rose 4.5% to $3.909 billion with adjusted EPS of $0.32 beating consensus near $0.26.	High
Valuation	At $19.24, KVUE traded near 22.9x trailing EPS, 15.8x forward EPS, 2.4x sales, 20.3x free cash flow, and a 4.37% dividend yield using audited tool math.	Medium-high
Technical trend	KVUE closed near $19.24 on July 31, 2026, above the 50-day and 200-day moving averages near $18.53 and $17.52, with 14-day RSI near 53 and a 52-week range of $14.02 to $22.29.	Medium
Risk level	Key risks are deal delay or break, KMB share price moves, Tylenol autism and ADHD litigation, decongestant advertising claims, weak organic volume, retailer inventory swings, tariff and FX pressure, and brand share erosion.	Medium-high
AI confidence	The descriptive research has high data confidence. The forecast has lower certainty because the path depends on the merger close, KMB shares, the August 6 Q2 report, and litigation outcomes.	High data confidence
Investment certainty	Investment certainty is medium. KVUE has recognizable brands and cash flow, but the near-term payoff is transaction-linked rather than a clean long-term compounding setup.	Medium

KVUE AI stock forecast

KVUE AI Stock Forecast Scenarios

The KVUE AI stock forecast uses scenario math rather than a single price promise. The three-year stand-alone framework around the July 31, 2026 close of $19.24 and the 2026 adjusted EPS consensus of $1.18 produced a bearish area near $14, a base area near $22, and a bullish area near $33, but the pending Kimberly-Clark transaction anchors the near-term path. Kenvue shareholders are set to receive $3.50 cash plus 0.14625 Kimberly-Clark shares per KVUE share, worth about $19.49 at the July 31, 2026 KMB close of $109.31, so the practical range narrows toward deal value unless the transaction fails.

Bullish case

$21 to $24

More likely if the Kimberly-Clark deal closes on expected terms, KMB shares hold firm or rise, Q2 2026 results beat, Skin Health and Beauty recovery continues, and legal risk stays bounded.

Base case

$18.5 to $21

More likely if the deal progresses toward a 2026 close but the spread stays partly open, KMB shares trade near current levels, EPS grows slowly, and the market values KVUE near the cash-and-stock consideration.

Bearish case

$12 to $15

More likely if the acquisition fails or is delayed materially, KMB shares fall sharply, Tylenol autism and ADHD claims expand, organic volume stays negative, or consumer staples multiples compress.

KVUE AI technical analysis

KVUE AI Technical Analysis

KVUE AI technical analysis is constructive but neutral as of the August 2, 2026 data cutoff. The stock closed near $19.24 on July 31, 2026, above its 50-day moving average near $18.53 and its 200-day moving average near $17.52, with 14-day RSI near 53 and 14-day ADX near 23, showing a mild uptrend without overbought momentum.

Level	Value	Why it matters
Current price	$19.24	StockAnalysis.com reported the July 31, 2026 close at $19.24, down 0.36% on the day and down 11.25% over 52 weeks.
Near support	$18.95 to $19.10	The July 31 session low was $18.95, with nearby support near the $19.10 area from recent consolidation.
Deeper support	$18.53	Barchart and StockAnalysis.com both placed the 50-day moving average near $18.53 on July 31, 2026, the first major trend reference.
Long-term support	$17.52	The 200-day moving average sat near $17.52, the larger trend line if short-term support fails.
Near resistance	$19.83 to $20.05	The average analyst target of $19.83 sits just overhead, with the July 28 session high near $20.05 as a chart ceiling.
52-week range	$14.02 to $22.29	StockAnalysis.com listed the 52-week low and high, framing the broader range after the stock fell 11.25% over the past year.
50-day moving average	$18.53	Price held above this average on July 31, 2026, supporting the short-term trend but leaving limited room before it turns flat.
200-day moving average	$17.52	Price remained above this long-term average, keeping the broader trend profile positive.
100-day moving average	$17.97	Barchart reported the 100-day moving average near $17.97, between the 50-day and 200-day lines.
Momentum	RSI near 53, ADX near 23	14-day RSI was near 53.24 and 14-day ADX near 22.56 on Barchart, indicating a modest uptrend that is not overbought.
Volume	About 18 million average shares	Barchart listed 20-day average volume near 18.9 million shares and StockAnalysis.com near 17.9 million on July 31, 2026.
Volatility	Moderate near 21%	Barchart reported 14-day historical volatility near 20.9%, so position sizing should account for swings around earnings and merger news.
Invalidation	Close below $18.53, then $17.52	A decisive close below the 50-day moving average near $18.53 would weaken the short-term setup; a close below the 200-day near $17.52 would damage the larger trend.

KVUE AI trading strategy

KVUE AI Trading Strategy Framework

The KVUE AI trading strategy is a rules-based framework for a defensive stock with deal exposure. It is not personal advice and should be paired with live quotes, merger filings, KMB price checks, the August 6 Q2 earnings report, and position sizing rules.

Trend-following setup

Watch for KVUE to hold above the $18.53 to $19.10 support zone and clear the $19.83 to $20.05 zone with volume above the recent average, while the 50-day moving average keeps rising.

A close below the 50-day moving average or a failed breakout after merger news should invalidate the short-term setup.

Mean-reversion setup

If KVUE pulls back toward the 50-day moving average near $18.53 or the 200-day near $17.52 without a new deal, litigation, or earnings problem, compare the price to the cash-and-stock consideration of about $19.49 and to the KMB price.

Do not treat the dividend yield alone as downside protection. A broken transaction, a falling KMB share price, or expanding Tylenol claims can reset the valuation quickly.

Fundamental monitor

Track Kimberly-Clark deal milestones, KMB share price, the August 6 Q2 2026 report, organic volume, Skin Health and Beauty recovery, Self Care demand, Essential Health share trends, free cash flow, debt, tariffs, FX, and legal disclosures.

Reduce confidence if EPS growth comes mainly from cost cuts while organic volume stays negative or if deal completion risk rises.

Investment research summary

Four-master Research Compression

Business essence

Kenvue sells trusted self-care and personal-care products that consumers buy repeatedly for pain relief, allergy, oral care, wound care, skin care, baby care, and daily hygiene.

Moat

The moat is brand memory plus distribution. Tylenol, Listerine, Band-Aid, Zyrtec, Aveeno, Neutrogena, and Johnson's earn shelf space because consumers recognize them and retailers need dependable traffic-driving brands.

Munger risk inversion

The thesis fails if the Kimberly-Clark deal breaks or slips, legal liabilities expand beyond current reserves, retailers keep reducing inventories, brand trust weakens, or cost savings mask a deeper volume problem.

Management

Management is less a pure stand-alone allocator now and more a transition steward. The key test is preserving brand momentum, cash flow, and employee focus while the acquisition process continues toward a 2026 close.

Industry trend

Consumer health benefits from aging populations, self-care adoption, trusted OTC brands, and global household penetration, but growth is slower than high-tech or biotech and is sensitive to private label competition.

Valuation and margin of safety

The current price sits slightly below the implied deal value of about $19.49 based on the July 31, 2026 KMB close, but the real value floats with KMB shares. Stand-alone margin of safety is only moderate because organic growth is low and litigation overhangs the brands.

Source-backed data

KVUE Data Table

Every metric below includes a source and last verification date.

Metric	Value	Source	Last verified
KVUE price	$19.24 at the July 31, 2026 close	StockAnalysis.com real-time quote	July 31, 2026
Market capitalization	$36.94 billion, verified as $19.24 x 1.92 billion shares with 0.00% deviation	financial_rigor.py market cap verification	August 2, 2026
Shares outstanding	1.92 billion common shares outstanding	StockAnalysis.com and Kenvue Q1 2026 Form 10-Q cross-check	July 28, 2026
FY2025 net sales	$15.124 billion, down 2.1% year over year	Kenvue FY2025 results and StockAnalysis.com financials	July 28, 2026
FY2025 net income	$1.470 billion, with FY2025 EPS of $0.76	StockAnalysis.com financials and Kenvue FY2025 results	July 28, 2026
TTM results	TTM revenue of $15.292 billion, net income of $1.622 billion, EPS of $0.84, and free cash flow of $1.823 billion	StockAnalysis.com financials	July 28, 2026
Q1 2026 results	Net sales of $3.909 billion up 4.5%, net income of $474 million, EPS of $0.25, free cash flow of $350 million	Kenvue Q1 2026 results and StockAnalysis.com income statement	July 28, 2026
Q1 2026 adjusted EPS	$0.32 versus consensus near $0.26, with net sales above consensus	Kenvue Q1 2026 results and TheFly	May 7, 2026
TTM segment revenue mix	Self Care $6.410B, Skin Health and Beauty $4.196B, Essential Health $4.686B	StockAnalysis.com financials segment breakdown	July 28, 2026
Balance sheet	Cash and investments of $1.075 billion, total debt of $8.661 billion, net debt of about $7.586 billion	StockAnalysis.com balance sheet	July 28, 2026
TTM cash flow	Operating cash flow of $2.258 billion, capital expenditures of $435 million, free cash flow of $1.823 billion	StockAnalysis.com cash flow statement	July 28, 2026
Valuation check	22.91x trailing EPS, 15.75x forward EPS, 2.42x sales, 20.26x free cash flow, 3.48x book value, 4.37% dividend yield	financial_rigor.py valuation verification and StockAnalysis.com	August 2, 2026
Merger consideration	$3.50 cash plus 0.14625 Kimberly-Clark shares per KVUE share, worth about $19.49 at the July 31, 2026 KMB close of $109.31	Kenvue and Kimberly-Clark transaction filings with financial_rigor.py calculation	July 31, 2026
KMB reference price	$109.31 at the July 31, 2026 close	StockAnalysis.com real-time quote	July 31, 2026
Dividend	$0.84 annual dividend for a 4.37% yield, quarterly dividend raised 1.2% to $0.21 on July 29, 2026, ex-dividend August 12, 2026	StockAnalysis.com dividend data and Kenvue press release	July 29, 2026
Analyst consensus	Hold with an average target of $19.83 across 14 analysts, low $18 and high $23, median $19.5	StockAnalysis.com forecast	July 23, 2026
Analyst rating mix, July 2026	1 Strong Buy, 1 Buy, 12 Hold, 0 Sell out of 14 analysts	StockAnalysis.com forecast recommendation trends	July 23, 2026
Recent analyst target updates	Barclays $18 to $19, UBS $18 to $20, Citi $19, RBC Capital $21, Canaccord Genuity $18	StockAnalysis.com forecast latest forecasts	July 23, 2026
2026 and 2027 consensus estimates	FY2026 revenue estimate $15.63B with adjusted EPS $1.18, FY2027 revenue $16.02B with adjusted EPS $1.24	StockAnalysis.com forecast financial forecast	July 23, 2026
Technical snapshot	50-day MA near $18.53, 100-day MA near $17.97, 200-day MA near $17.52, 14-day RSI near 53.24, 14-day ADX near 22.56	Barchart and StockAnalysis.com technical snapshots	July 31, 2026
52-week range and beta	$14.02 to $22.29 range, beta of 0.44, 52-week price change of -11.25%	StockAnalysis.com statistics	August 2, 2026
Short interest	61.56 million shares short, 3.21% of shares outstanding, 2.89 days to cover	StockAnalysis.com statistics short selling	August 2, 2026
Q2 2026 earnings date	August 6, 2026, before market open	Kenvue press release	July 23, 2026
Tylenol with Naproxen approval	FDA approved the first OTC fixed-dose acetaminophen and naproxen combination on July 24, 2026	Reuters and TheFly	July 24, 2026
Tylenol autism and ADHD litigation	A federal appeals court revived hundreds of private lawsuits on July 13, 2026	Reuters	July 13, 2026
Decongestant false ad litigation	An appeals court on July 30, 2026 revived portions of nationwide maximum strength decongestant claims involving drugmakers and retailers	Reuters	July 30, 2026

Frequently Asked Questions

Read the JNJ AI stock analysis View KO AI stock forecast Explore AI Stock Picker Generate an AI trading strategy Screen consumer staples stocks

This KVUE AI stock analysis is an informational tool only and is not investment advice, legal advice, tax advice, or a recommendation to buy or sell securities. Forecast scenarios are based on available data as of August 2, 2026, and may be wrong, incomplete, or outdated after new earnings, litigation, merger, market, or macro developments. Always verify live prices, filings, merger terms, and your own risk constraints before making financial decisions.